A recent analysis conducted retrospectively on more than 50,000 women tested with multigene panels for HBOC observed a higher risk of BC in carriers of MSH6 and PMS2 mutations compared to older studies, which focused on identifying the risk of BC in patient cohorts selected on account of having colorectal cancer. This evidence concerns the gene PMS2 and colorectal cancer.